Will you be in the Bay Area during the #JPM conference? Come and meet the TOLREMO team, CEO Stefanie Flückiger-Mangual and CBO Jessica Corson, who will be in San Francisco from January 8-11. Connect with us to discuss our lead candidate TT125-802 and our approach in leveraging transcriptional cancer drug resistance to transform the treatment landscape of solid tumors.
TOLREMO therapeutics’ Post
More Relevant Posts
-
Bispecific ADCs have the potential to deliver enhanced efficacy over canonical ADC approaches for the same payload dose, and this is exactly what we see with ALM-401. Great to see this novel engineered Bispecific ADC progressing forward.
Almac Discovery announces the nomination of ALM-401 as a First in Class Bispecific Next Generation ADC for the treatment of refractory lung cancer to progress into pre-clinical development. Read more in our latest press release: https://hubs.li/Q02yXZyZ0
-
-
According to results from the phase 2 NICHE-2 trial, neoadjuvant nivolumab plus ipilimumab showed promising safety and response results among patients with locally advanced mismatch repair-deficient colon cancer. Learn more: https://lnkd.in/ec2bZMTN
-
-
We know that cancer is a proteogenomic network. How do you define disease-specific nodes in the network to develop combination therapy? Dr. Michael Castro, M.D., CMO at Cellworks, presents a groundbreaking case report about using multiple synthetic lethal vulnerabilities to design a leptomeningeal glioblastoma combination therapy– which has been published by Frontiers in Oncology. You can read the case report here: https://lnkd.in/gbPvS_FP #PrecisionMedicine #Glioblastoma #Cellworks #InnovationInOncology
-
-
Save the date 🗓️ for an exclusive live webinar that you won't want to miss! Join us on 12th March 2024, from 15:00 to 16:00 GMT, as we delve into Improved nodal staging using accurate and quantitative molecular lymph node analysis in prostate cancer – outcome of the POPCORN study. 𝗞𝗲𝘆 𝘁𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀: ✅ Implementing OSNA within the clinical workflow ✅ How molecular whole lymph node analysis can support management of prostate cancer patients ✅ Results from the multicentric POPCORN study: improved nodal staging using OSNA https://lnkd.in/dyctTane
-
Phase 2 nonrandomized controlled trial of bintrafusp alfa in patients with recurrent or metastatic cervical cancer met its primary end point, which may support the further exploration of bifunctional molecules, particularly those targeting TGF-β and PD-L1. https://ja.ma/3y2B4Cd
-
-
Leading the way in collaborative compounds, drug discovery and targeted therapeutics - what a joy to share that the joint effort of Moderna & Carisma Therapeutics has yielded the first in a series of candidates. This nomination leverages mRNA-based in vivo CAR-M to develop a novel cell therapy targeting GPC3 in solid tumors - and which is known to be highly expressed in hepatocellular carcinoma. "HCC is the most prevalent type of liver cancer and the fastest-rising cause of cancer-related death in the U.S." Let's bring forward some new options for patients! #HCC #LiverCancer #PatientPotential #mRNA #Macrophage #Monocyte #GPC3 #Glypican3 #collaboration #drugdiscovery #targetedtherapeutics #celltherapy #celliconvalley #immunotherapy #solidtumor #NasdaqCARM
We are excited to announce the nomination of the first Development Candidate under our collaboration with Moderna, Inc. The Development Candidate is an in vivo CAR-M targeting Glypican-3 and is designed to treat solid tumors, including hepatocellular carcinoma, the most prevalent type of liver cancer and the fastest-rising cause of cancer-related death in the U.S. Read more in the press release here: https://lnkd.in/gpeaEx_v #Immunotherapy #CancerResearch #SolidTumors #LiverCancer #HCC
-
-
🌈 🌈 Dr. Yang Hao et al wrote #HighlyCitedPaper "#Combinatorial Therapeutic Approaches with Nanomaterial-Based Photodynamic Cancer Therapy" You can find it at: https://shorturl.at/oGSey
-
-
💡 The PSA testing market is booming, set to soar from $6 billion in 2022 to a staggering $19 billion by 2033. But this growth sparks a crucial question: Are we investing in the right approach to prostate cancer screening? 🔍 Explore the clinical and economic dimensions of PSA testing in my latest Medium article.
The PSA Testing Conundrum: Market Surge Despite Clinical Limitations
link.medium.com
-
🧬 In a retrospective analysis, Arnab Basu, M.D., MPH, Assistant Professor in the UAB Division of Hematology and Oncology, found that patients with muscle-invasive bladder cancer who had detectable circulating tumor DNA before radical cystectomy had shorter disease-free survival and higher recurrence rates. Learn More ➡️ https://lnkd.in/ekK6BK3N
-
-
In this edition, we are sharing an update on the: 💡 Selective RET Inhibitor Selpercatinib Demonstrated Favorable Clinical Outcome over Cabozantinib or Vandetanib in RET-mutant Medullary Thyroid Cancer. 💡 DESTINY-PanTumor02: The ADC trastuzumab deruxtecan (T-DXd) showed activity in HER2-expressing solid tumors. 💡 Detection Discrepancies in HER2 Amplification: Implications for Therapeutic Strategies - Insights from the MOUNTAINEER Study Presented at the 2023 #ASCO and #ESMO Annual Meetings. Find out more on our #ACTGenomics Blog: https://lnkd.in/g-WU-Upi
-
